SELECT- The effect of Semaglutide on cardiovascular outcomes in people who are overweight or obese

SELECT- The effect of Semaglutide on cardiovascular outcomes in people who are overweight or obese

Brief description of study

This study will demonstrate that semaglutide e weekly lowers the risk of cardiovascular events, in subjects with established CV disease and overweight or obesity in people 45 years or older .

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    cardiovascular overweight obese,Heart attack,Stroke,Overweight,Obese
  • Age: Between 45 Years - 99 Years
  • Gender: All

Heart attack Stroke Overweight Obese MALE AND FEMALE OVER AGE 45

Updated on 22 Jun 2022. Study ID: 831615

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center